Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Cost of Revenue of $24.8 million for Q1 2026, up 21.57% year-over-year from $20.4 million in Q1 2025, and down 5.47% quarter-over-quarter from $26.2 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Cost of Revenue history runs 11 years deep, the most recent figure standing at $24.8 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 21.57% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $93.4 million (up 17.8% YoY), while the FY2025 annual figure was $89.0 million, up 8.75% from the prior year.
- Cost of Revenue for Q1 2026 stood at $24.8 million, down from $26.2 million in the prior quarter.
- The five-year high for Cost of Revenue was $26.2 million in Q4 2025, with the low at $1.7 million in Q1 2023.
- The 5-year median for Cost of Revenue is $18.2 million (2024), against an average of $14.6 million.
- The sharpest annual moves came in 2022 and 2024: Cost of Revenue slumped 77.54% in 2022, then jumped 1276.78% in 2024.
- Acadia Pharmaceuticals' Cost of Revenue stood at $2.4 million in 2022, then soared by 641.44% to $17.9 million in 2023, then advanced by 21.87% to $21.8 million in 2024, then gained by 20.28% to $26.2 million in 2025, then dropped by 5.47% to $24.8 million in 2026.
- Business Quant data shows ACAD's Cost of Revenue at $24.8 million in Q1 2026, $26.2 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 28.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.32 Mn |
| Jun 30, 2026 | 28.32 Mn |
| Mar 31, 2026 | 24.79 Mn |
| Mar 31, 2026 | 24.79 Mn |
| Dec 31, 2025 | 26.23 Mn |
| Dec 31, 2025 | 26.23 Mn |
| Sep 30, 2025 | 21.65 Mn |
| Sep 30, 2025 | 21.65 Mn |
| Jun 30, 2025 | 20.73 Mn |
| Jun 30, 2025 | 20.73 Mn |
| Mar 31, 2025 | 20.39 Mn |
| Mar 31, 2025 | 20.39 Mn |
| Dec 31, 2024 | 21.80 Mn |
| Dec 31, 2024 | 21.80 Mn |
| Sep 30, 2024 | 18.86 Mn |
| Sep 30, 2024 | 18.86 Mn |
| Jun 30, 2024 | 18.23 Mn |
| Jun 30, 2024 | 18.23 Mn |
| Mar 31, 2024 | 22.95 Mn |
| Mar 31, 2024 | 22.95 Mn |